Entera Bio shares Phase 2 data and Phase 3 design for oral PTH tablet
Tweet Send to a Friend
Entera Bio Ltd. (NASDAQ: ENTX) presented post-hoc Phase 2 data and its Phase 3 study design for EB613, an oral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




